Twist Bioscience Corp (TWST) — SEC Financial Statements & Analysis

Twist Bioscience Corp (TWST) is a biological products, (no diagnostic substances) company, incorporated in DE. Twist Bioscience Corp trades on Nasdaq as: TWST. Twist Bioscience Corp (TWST)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, Twist Bioscience Corp carries a market cap of $6.42B, a P/E ratio of -46.96x, a P/B ratio of 14.40x, a P/S ratio of 14.87x, an enterprise value of $6.30B, and an EV/EBITDA multiple of -52.76x. On profitability, it posts a gross margin of 51.97%, an operating margin of -33.58%, a net margin of -31.66%, a Return on Equity (ROE) of -29.59%, a Return on Assets (ROA) of -20.78%, and a Return on Invested Capital (ROIC) of -46.75%. Per share, it reports EPS of $-2.19, diluted EPS of $-2.19, free cash flow per share of $-1.49, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 19.19% year-over-year, net income growth of 60.49% year-over-year, and EPS growth of 54.30% year-over-year. On the balance sheet, it maintains a current ratio of 2.67x, a quick ratio of 1.93x, working capital of $201.04M, a debt-to-equity ratio of 0.51x, a debt ratio of 0.34, an interest coverage ratio of -940.66x, free cash flow of $-93.12M (TTM), and net debt of $-119.57M. Figures sourced from SEC EDGAR.

Market Cap

$6.42B

P/E TTM

-46.96x

EPS TTM

$-2.19

P/B TTM

14.40x

ROE TTM

-29.59%

ROA TTM

-20.78%

Debt To Equity

0.51x

Free Cash Flow TTM

$-93.12M

Net Revenue TTM Growth 1Y

19.19%

Data as of 2026-06-30 · Source: SEC EDGAR